Charles Schwab Investment Management Inc. Has $8.40 Million Stock Holdings in Alphatec Holdings, Inc. $ATEC

Key Points

• Charles Schwab Investment Management Inc. reduced its holdings in Alphatec Holdings, Inc. by 2.1%, selling 17,897 shares and holding a total of 828,327 shares valued at approximately $8.4 million.
• Alphatec reported Q2 earnings of $0.02 per share, exceeding analysts' expectations, alongside a revenue of $185.54 million, up 27.5% year-over-year.
• Several research firms have given Alphatec a buy rating, with Barclays raising its price target to $22 and a consensus target price of $18.50 among six analysts.

Charles Schwab Investment Management Inc. lessened its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 2.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 828,327 shares of the medical technology company's stock after selling 17,897 shares during the period. Charles Schwab Investment Management Inc. owned about 0.57% of Alphatec worth $8,399,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Lido Advisors LLC boosted its position in Alphatec by 8.4% during the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after purchasing an additional 953 shares during the last quarter. Comerica Bank boosted its position in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in Alphatec by 13.4% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after purchasing an additional 1,552 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Alphatec by 0.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 288,967 shares of the medical technology company's stock valued at $2,653,000 after purchasing an additional 1,784 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Alphatec by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,809 shares of the medical technology company's stock valued at $650,000 after purchasing an additional 2,177 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Down 0.8%

NASDAQ ATEC traded down $0.13 during trading on Friday, hitting $15.90. 1,651,222 shares of the company traded hands, compared to its average volume of 2,698,129. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $16.47. The business has a fifty day simple moving average of $12.88 and a 200 day simple moving average of $11.74. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The company has a market capitalization of $2.35 billion, a P/E ratio of -14.07 and a beta of 1.02.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue for the quarter was up 27.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

ATEC has been the subject of a number of research reports. Wall Street Zen cut Alphatec from a "buy" rating to a "hold" rating in a research report on Saturday. Barclays reissued an "overweight" rating and set a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research report on Monday, June 16th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $20.00 target price on shares of Alphatec in a report on Friday, August 1st. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Alphatec currently has a consensus rating of "Buy" and an average price target of $18.50.

Insider Transactions at Alphatec

In other news, COO Scott Lish sold 36,081 shares of Alphatec stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $12.53, for a total value of $452,094.93. Following the transaction, the chief operating officer directly owned 708,855 shares in the company, valued at approximately $8,881,953.15. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of Alphatec stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel owned 438,331 shares in the company, valued at $6,535,515.21. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 410,247 shares of company stock worth $5,376,804. Company insiders own 22.80% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.